R&D | May 25, 2026
Lilly brings heavy oncology firepower to ASCO with plenary data across cancers
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
With standout ADC and t-cell engager response data across hard-to-treat cancers
Across more than 85 abstracts, AstraZeneca will showcase 10 approved medicines and 13 potential new therapies
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
The approval was granted by Agenzia Italiana del Farmaco
Transition to a fermentation-based globally integrated CDMO platform
Approval of device in Australia for treating locally advanced pancreatic cancer alongside gemcitabine-based chemotherapy
Organizations that embrace it thoughtfully today will help shape a healthier tomorrow, for India and beyond
SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region
US federal jury finds Japanese drugmaker liable for anticompetitive agreement delaying generic version of constipation drug Amitiza
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
